ANL

Adlai Nortye (ANL)

About Adlai Nortye (ANL)

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.

Details

Daily high

$7.29

Daily low

$6.93

Price at open

$7.07

52 Week High

$12.09

52 Week Low

$0.88

Market cap

218.3M

Dividend yield

0.00%

Volume

9,026

Avg. volume

197,692

P/E ratio

Adlai Nortye News